基于竞争风险模型在妊娠11周前采集血样中测量胎盘生长因子筛查子痫前期
研究纳入丹麦PRESIDE前瞻性多中心研究的8386名孕妇,分析常规早孕期联合筛查血样中胎盘生长因子(PlGF)的分布特征及对子痫前期(PE)的预测效能。结果显示,10周采集的血样中早产型PE的PlGF中位数倍数显著低于未患病孕妇,但10周前采集的血样中PlGF中位数倍数在PE与未患病孕妇间无显著差异。结论认为使用FMF早孕期筛查模型时PlGF采样孕周可从11-14周扩展至10-14周,但10周前采样的证据不足。
要点
- 10周采集血样中早产型PE的PlGF中位数倍数显著低于未患病孕妇。
- 10周前采集血样中PlGF中位数倍数在PE与未患病孕妇间无显著差异。
- 使用FMF早孕期筛查模型时PlGF采样孕周可从11-14周扩展至10-14周。
核心结论
- 使用FMF早孕期筛查模型评估PE风险时,PlGF采样孕周可从11-14周扩展至10-14周。
- 10周前采集血样中使用PlGF的证据不足。
研究设计与样本
- 研究人群为丹麦子痫前期筛查(PRESIDE)研究中的孕妇,纳入有常规早孕期联合筛查(cFTS)血样(采集于8-14周)且测量PlGF者。
- PRESIDE为前瞻性多中心研究,旨在丹麦人群中探究胎儿医学基金会(FMF)早孕期PE筛查算法的预测效能。
- 本研究中cFTS血样的PlGF血清浓度于2021年1月至6月间分批检测。
主要发现
- 共纳入8386名孕妇,PE发生率在<37周为0.7%,在≥37周为3.0%。
- 10周采集的血样中,早产型PE(<37周)孕妇的PlGF中位数倍数(MoM)显著低于未患病孕妇。
- 10周前采集的血样中,PE与未患病孕妇的PlGF MoM无显著差异。
临床怎么用
- 使用FMF早孕期筛查模型评估PE风险时,可考虑将PlGF采样孕周从11-14周扩展至10-14周。
- 10周前采集血样中PlGF的临床使用证据不足。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the distributional properties and assess the performance of placental growth factor (PlGF) measured in blood samples collected before 11 weeks' gestation in the prediction of pre-eclampsia (PE). METHODS: The study population consisted of pregnant women included in the Pre-eclampsia Screening in Denmark (PRESIDE) study with a PlGF measurement from the routine combined first-trimester screening (cFTS) blood sample collected at 8-14 weeks' gestation. PRESIDE was a prospective multicenter study investigating the predictive performance of the Fetal Medicine Foundation (FMF) first-trimester screening algorithm for PE in a Danish population. In the current study, serum concentration of PlGF in the cFTS blood samples was analyzed in batches between January and June 2021. RESULTS: A total of 8386 pregnant women were included. The incidence of PE was 0.7% at < 37 weeks' gestation and 3.0% at ≥ 37 weeks. In blood samples collected at 10 weeks' gestation, PlGF multiples of the median (MoM) were significantly lower in pregnancies with preterm PE < 37 weeks compared to unaffected pregnancies. However, PlGF MoM did not differ significantly between pregnancies with PE and unaffected pregnancies in samples collected before 10 weeks' gestation. CONCLUSIONS: The gestational-age range for PlGF sampling may be expanded from 11-14 to 10-14 weeks when assessing the risk for PE using the FMF first-trimester screening model. There is little evidence to support the use of PlGF in blood samples collected before 10 weeks' gestation. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Riishede I, Ekelund CK, Sperling L, et al. Screening for pre-eclampsia with competing-risks model using placental growth factor measurement in blood samples collected before 11 weeks' gestation. Ultrasound Obstet Gynecol. 2024. PMID: 37698230. doi:10.1002/uog.27462
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。